Drugs / ELI-002 7P
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07671339 | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELI-002 7P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07671339 ↗ |
| Modality | Vaccine | “ELI-002 7P vaccine” NCT07671339 ↗ |
| Route | Subcutaneous | “a subcutaneous (SC) injection under the skin” NCT07671339 ↗ |
| Target | KRAS | “a lipid-conjugated Kristin-Ras (KRAS) therapeutic cancer immunotherapy” NCT07671339 ↗ |